Editor's Note

Generally, at StockNight we tend to feature financial news items that have come out after market but sometimes news falls into our hands that is of such significance that we distribute to our members as soon as possible. We just received authorization moments ago to send this news to our members. Read on!
 

Elast Technologies Inc.

Elast Technologies Inc. (OTCBB: ELTI) is presently engaged in two unique industries using applications of its patented technology. The first, the innovative Electronic Allergo Sensitivity Test, is an instrument with which allergies and food and chemical sensitivities may be detected without invading the body. Another application, the Bio-Potential Instrument, allows chiropractors the means with which to gauge the benefit of chiropractic care. The merger with PTS Inc. today brings yet another unique body of technology under the ELTI listing, some of whch could be affected dramatically by Chinese admission to the World Trade Organization.  Click here to read CNN's take on China, Technology & the WTO.
 

Merger News

ELAST Technologies Merges with PTS, Inc.

PTS is committed to the development of a truly global trading platform to facilitate everyday business transactions. Through its pending joint venture with a major Shanghai information technology firm and the venture's forthcoming launch of a China based business-to-business platform PTS will take a major step towards this goal. PTS' China platform will permit real time business transactions such as electronic payments, contract fulfillment and the dissemination of financial information in China. Upon China's accession to the World Trade Organization PTS will be uniquely positioned to expand its platform globally conducting transactions of any size, anywhere, across multiple currencies.

Through this merger ELAST Technologies will be favorably positioned in two important and emerging fields, electronic payment and electronic medicine, and the potential presented by each is limitless. Moreover, ``ELAST's merger with PTS should assure early perfection and delivery of ELAST's diagnostic tools, as well as reduced engineering and production costs,'' predicts Thomas F. Krucker, President and CEO.

Currently, ELAST is engaged in the development of two separate diagnostic tools: its allergy testing device and its chiropractic outcome-measuring instrument. These instruments stem from the Company's identification of commercial applications for worldwide patents secured by its founder, Robert D. Milne, MD. A primary application is the innovative Electronic Allergo Sensitivity Test or the ELAST Device(TM). The ELAST Device(TM) is a non-invasive medical tool that is being designed to accurately diagnose allergies, as well as food and chemical sensitivities. ELAST Technologies holds the patents, trademarks and legal rights to manufacture, sell and lease its electronic allergy-testing device and is making great strides in refining the prototype.

A second application of ELAST's technologies is ELAST's Bio-Potential Instrument. The Bio-Potential Instrument can provide doctors of chiropractic with the means to measure the damage of vertebral subluxations, as well as the normalizing effect of chiropractic adjustments. ELAST plans initial delivery of its Bio-Potential Instrument shortly.

Again, this is just part of the release. Click here to read it in its entirety: ELTI NEWS

Related links, Due Diligence & Financials:

Elast Technologies Corporate Home Page

More ELTI Financial Data

ELTI NEWS

New Feature! Question of the Day:  Will the Palestinian/Israeli cease fire last? Who should occupy the disputed land? Click here to comment.

Disclaimer & Safe Harbor Statement:

SafeHarbor:
This fact sheet contains “forward-looking statements” within the meaning of Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of the 1934.  These forward-looking statements can be identified by the use of forward-looking terminology such as “may”, “could”, “expected to” and “believes.”  Actual events or  performance involve risks and uncertainties that could differ materially from those anticipated in such forward-looking statements. Factors that could cause actual results to differ materially from those projected in forward-looking statements include competition, themanagement of our growth and the ability to deliver new products to market on time.  Such forward-looking statements are subject to other risks and uncertainties, which are detailed in the Company’s filings with the Securities and Exchange Commission. 

Disclaimer:
StockNight.com is being published by Integrity Media Inc. (IMI), a public relations firm.  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  This report is for information purposes only and should not be used as the basis for any investment decision.  IMI and/or its affilitiates and subcontractors have been compensated 321,875 restricted and free trading shares, for the preparation and dissemination of this report and previous public relations efforts. This compensation constitutes a conflict of interest as to IMI’s ability to remain objective in its communication regarding the subject company.  Write IMI for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934. IMI is not an investment advisor and this report is not investment advice.  This information is neither a solicitation to buy nor an offer to sell securities. Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice.  IMI and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned. Information contained herein may not be reproduced in whole or in part without the express written consent of Integrity Media Incorporated.